Skip to content

Released Feb 7, 2019, after the close

10-K filed Mar 18, 2019, 77 days after period end · 0001162194-19-000020

Q4 2018 · 10-K
Revenue$32.33M+16.5% vs Q4 2017+11.6% vs Q3 2018
Net Income-$14.78MderivedN/M vs Q4 2017N/M vs Q3 2018
EPS Diluted-$0.36N/M vs Q4 2017N/M vs Q3 2018
Gross Profitderived$18,811,000—
Operating Incomederived-$11,118,000N/M
Operating Cash Flowderived-$638,000N/M
Free Cash Flowderived-$658,000N/M
Margins · derived
Gross margin58.2%
Operating margin-34.4%−2.9 pt vs Q4 2017
Net margin-45.7%−8.0 pt vs Q4 2017

What the release said

The release

Same quarter

MetricQ4 2018Q4 2017Q4 2016Q4 2015
Revenue$32.33M$27.75M$25.08M$30.72M
Net Income-$14.78M-$10.46M-$17.70M-$12.88M
EPS Diluted-$0.36-$0.27-$0.61-$0.45

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR